BioTuesdays

Category - Markets

Axsome Therapeutics
Markets

BTIG ups Axsome Therapeutics PT to $48 from $25

BTIG raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $48 from $25 after the company announced positive Phase 2 data for its AXS-12 drug candidate for the treatment of cataplexy and excessive daytime...

December 4, 2019
STAAR Surgical
Markets

BTIG starts STAAR Surgical at buy: PT $46

BTIG initiated coverage of STAAR Surgical (NASDAQ:STAA) with a “buy” rating and $46 price target. The stock closed at $36.82 on Dec. 3. “We believe STAAR owns a superior refractive surgery option to the current standard...

December 4, 2019
TELA Bio
Markets

Piper Jaffray starts TELA Bio at OW; PT $17

Piper Jaffray initiated coverage of TELA Bio (NASDAQ:TELA) with an “overweight” rating and $17 price target. The stock closed at $12.31 on Dec. 2. TELA is a regenerative medicine company, with products used in hernia...

December 3, 2019
BeyondSpring Logo
Markets

WB starts BeyondSpring at outperform

William Blair launched coverage of BeyondSpring (NASDAQ:BYSI) with an “outperform” rating. The stock closed at $12.45 on Dec. 2. According to analyst Andy Hsieh, the Street is “undervaluing the clinical potential” of...

December 3, 2019
Galera Therapeutics
Markets

BTIG starts Galera Therapeutics at buy; PT $30

BTIG launched coverage of Galera Therapeutics (NASDAQ:GRTX) with a “buy” rating and $30 price target. The stock closed at $12.53. Galera is focused on developing superoxide dismutase mimetics, first‐in‐class medicines...

December 2, 2019
Centogene Logo
Markets

SVB Leerink starts Centogene at OP; PT $21

SVB Leerink initiated coverage of Centogene NV (NASDAQ:CNTG) with an “outperform” rating and price target of $21.The stock closed at $12.97 on Nov. 29. “We see Centogene as a leader in rare disease diagnostics...

December 2, 2019
BioCardia
Markets

Brookline starts BioCardia at buy; PT $22

Brookline Capital Markets launched coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and $22 price target. Near the close of trading on Nov. 27, the stock was quoted at $4.55. BioCardia is a developing CardiAMP...

November 29, 2019
Adamis Pharma
Markets

Dawson James cuts Adamis Pharma PT to $1 from $4

Dawson James reduced its price target for Adamis Pharmaceuticals (NASDAQ:ADMP) to $1 from $4 on the heels of an FDA complete response letter (CRL) for the company’s high-dose naloxone injection product for the treatment...

November 26, 2019
chemocentryx
Markets

SVB Leerink ups Chemocentryx PT to $50 from $27

SVB Leerink hiked its price target for Chemocentryx (NASDAQ:CCXI) to $50 from $27 after the company unveiled positive topline data from its Phase 3 ADVOCATE trial for avacopan. The stock closed at $8.06 on Nov. 25, but...

November 26, 2019
NextCure
Markets

BTIG starts NextCure at buy; PT $61

BTIG initiated coverage of NextCure (NASDAQ:NXTC) with a “buy” rating and $61 price target. The stock closed at $39.84 on Nov. 25. NextCure is developing first‐in‐class medicines to treat cancer and other immune‐related...

November 26, 2019